Braveheart Bio, Inc.

Overview

Compare with another stock.

• TickerBRVE on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersSan Francisco, California¹
• Incorporated inDE²
• Business addressOne Letterman Dr., Bldg. A, Ste. A4-300, San Francisco, Ca 94129²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Braveheart Bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Braveheart Bio, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerTravis Murdoch Aug 5, 2026 to now⁴
• PresidentTravis Murdoch Aug 5, 2026 to now⁴
• Chief financial officerJames Paul Rickey Aug 5, 2026 to now⁵

Timeline

1. Sep 8, 20268-K Results of operations¹⁴
2. Aug 7, 20268-K Bylaws or fiscal year changed¹⁵
3. Aug 5, 2026New chief executive Travis Murdoch becomes CEO⁴

Calendar

Coming up

1. Dec 8, 2026Reports results for the quarter ending Sep/2026¹⁶

When it reported results

1. Sep 8, 2026Reported quarterly or annual results¹⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

46 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 29 insider forms, 4 large holders, 10 other. The latest 20:

1. Sep 10, 2026SCHEDULE 13D/A EDGAR
2. Sep 8, 202610-Q EDGAR
3. Sep 8, 20268-K EDGAR
4. Aug 18, 2026SCHEDULE 13D EDGAR
5. Aug 14, 20263 EDGAR
6. Aug 14, 2026SCHEDULE 13D EDGAR
7. Aug 14, 2026SCHEDULE 13G EDGAR
8. Aug 11, 20264 EDGAR
9. Aug 11, 20264 EDGAR
10. Aug 11, 20264 EDGAR
11. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
12. Aug 7, 20268-K EDGAR
13. Aug 7, 20264 EDGAR
14. Aug 7, 20264 EDGAR
15. Aug 7, 20264 EDGAR
16. Aug 7, 20264 EDGAR
17. Aug 7, 20264 EDGAR
18. Aug 7, 20264 EDGAR
19. Aug 7, 20264 EDGAR
20. Aug 7, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 10 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• ORBIMED ADVISORS LLCSCHEDULE 13D/A, 2 filings Aug 18, 2026 to Sep 10, 2026¹⁷
• AH Bio Fund IV, L.P.SCHEDULE 13D, 1 filing Aug 14, 2026¹⁸
• Frazier Life Sciences Public Fund, L.P.SCHEDULE 13G, 1 filing Aug 14, 2026¹⁹

SEC filer profile

How Braveheart Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARBraveheart Bio, Inc.¹
• CIK0002131524
• Employer ID (EIN)99-2981994¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressOne Letterman Dr., Bldg. A, Ste. A4-300, San Francisco, CA 94129¹
• Phone(415) 707-6312¹
• Shares outstanding90,038,969 as of Sep 3, 2026³
• On EDGAR sinceApr 29, 2026¹
• Filings46 in all: 3 (15), 4 (14), 8-K (2), SCHEDULE 13D (2), 10-Q (1), 424B4 (1), 8-A12B (1), CERT (1)¹
  All 17 form types

  DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

• Latest filingsQuarterly report (10-Q) Sep 8, 2026
  Latest 8-K (8-K) Sep 8, 2026